Contrast-Induced Acute Kidney Injury in Patients With Renal Dysfunction Undergoing a Coronary Procedure and Receiving Non-Ionic Low-Osmolar Versus Iso-Osmolar Contrast Media

What is optimal revascularization strategy in patients with multivessel coronary artery disease in non-ST-elevation myocardial infarction? Multivessel or culprit-only revascularization

“…Large amounts of iodized contrast were needed for multivessel PCI and this problem could not enable interventional cardiologist to revascularize multivessels [15]. However, contrastinduced nephropathy was developed less frequently with low-or isoosmolar and non-ionic contrast [16]. Patients who underwent PCI in the present study did not show significant differences in developing acute kidney injury between both groups.…”

Contrast-Induced Acute Kidney Injury: The At-Risk Patient and Protective Measures

“…Through an ad hoc subgroup analysis, patients with high contrast volumes greater than 340 mL receiving iodixanol had significantly lower rates of CI-AKI than iomeprol [26]. Alexopoulos et al [27], in a subgroup analysis of an ascorbic acid trial, confirmed the findings by Wessely et al [26], whereby patients receiving iso-osmolar contrast had lower rates of CI-AKI, but were not significantly different. Laskey et al [28] conducted a trial to compare iodixanol with iopamidol among 526 patients with chronic kidney disease undergoing PCI.…”

Renal safety in pediatric imaging: randomized, double-blind phase IV clinical trial of iobitridol 300 versus iodixanol 270 in multidetector CT

“…In a recent meta-analysis by Heinrich et al [32], a reduction in nephrotoxicity was seen only when iodixanol was compared with iohexol, but no benefit was seen when this IOCM was compared with other LOCM. The results of Alexopoulos et al [33] showed that no differences in contrast-induced acute kidney injury incidence were apparent among patients receiving nonionic iso-osmolar iodixanol and nonionic low-osmolar contrast agents.…”